DOCSLIB.ORG

A Novel Orexin Antagonist from a Natural Plant Was Discovered Using Zebrafish Behavioural Analysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Novel Orexin Antagonist from a Natural Plant Was Discovered Using Zebrafish Behavioural Analysis European Review for Medical and Pharmacological Sciences 2020; 24: 5127-5139 A novel orexin antagonist from a natural plant was discovered using zebrafish behavioural analysis M. YAMANAKA1, H. IWATA2, K. MASUDA2, M. ARAKI2, Y. OKUNO2, M. OKAMURA1, J. KOIWA1, T. TANAKA1 1Department of Systems Pharmacology, Mie University, Graduate School of Medicine, Tsu, Mie, Japan 2Graduate School of Medicine, Kyoto University, Kyoto, Japan Abstract. – OBJECTIVE: Phenotypic screen- ing methods. However, these methods do not focus ing is one of the most practical approaches on the interactions of the whole organism’s activity, to the identification of mediators of behaviour, resulting in difficulty to ensure success at an organ- since it is difficult to model brain function in vi- ismal level. To overcome these difficulties and to tro, at a cellular level. We used a zebrafish (Da- nio rerio) behavioural assay to discover novel, increase the efficiency of screening, pharmacolog- natural, neuroactive compounds. ical researchers have adopted a phenotype-based MATERIALS AND METHODS: A zebrafish screening method. Many first-in-class drugs have behavioural assay was performed for seven been discovered by the phenotype-based approach, natural compounds, obtained from plants. The rather than the target-based approach1. behavioural profiles were compared to those of Phenotypic screening is one of the most prac- known psychoactive drugs. We characterised a natural compound exhibiting a behaviour profile tical approaches to the identification of mediators similar to that of suvorexant, using in silico, in of behaviour, since it is difficult to model brain vitro and microarray expression analysis. function in vitro, at a cellular level. During the last RESULTS: The behavioural analysis performed decade, zebrafish behaviours have become one of in this study classified central nervous system the major screening systems used to identify neu- drugs according to their mechanism. Zebrafish roactive compounds, through behaviour-based b treated with a natural compound, 8 -(4'-Hydroxy- chemical screening2. Zebrafish are vertebrates, tigloyloxy) costunolide (8b), showed behaviour and the structure and function of their organs profiles similar to those of zebrafish treated with 3,4 suvorexant, a known orexin antagonist. This be- and tissues are similar to those of humans . The havioural assay was validated using in silico and receptors and neurotransmitters are highly con- in vitro assays, which revealed that the new com- served between humans and zebrafish5. pound was a dual orexin receptor antagonist. In In this study, we attempted to discover novel, addition, transcriptome analysis suggested that natural, neuroactive compounds by phenotypic 8b might regulate the nuclear factor-κB (NF-κB) related pathway. screening, using zebrafish behavioural analysis. CONCLUSIONS: We conclude that zebrafish As a test case, we focused on a natural compound phenotypic screening, combined with in silico exhibiting a behaviour profile similar to that of su- assays and gene expression profiling, is a useful vorexant, a well-known orexin receptor antagonist. strategy to discover and characterize novel ther- Orexins are neuropeptides involved in the reg- apeutic compounds, including natural products. ulation of the sleep-wake cycle, feeding pattern, 6,7 Key Words: energy balance, and stress in mammals . Dys- Zebrafish, Behaviour, Phenotype-based screening, regulation or loss of orexin signalling has been Sleep, Orexin. linked to narcolepsy8-10. Several dual orexin re- ceptor antagonists have been investigated as po- tential treatments for insomnia, and one of them, suvorexant, received approval by the US Food Introduction and Drug Administration (FDA), in 2014, for the treatment of such a condition11. Although these Many successful therapeutics have been dis- drugs have an outstanding safety profile, there are covered using cell-based and biochemical screen- concerns regarding the use of these drugs, due Corresponding Author: Toshio Tanaka, MD; e-mail: [email protected] 5127 M. Yamanaka, H. Iwata, K. Masuda, M. Araki, Y. Okuno, M. Okamura, J. Koiwa, T. Tanaka to potential side-effects and lack of evaluation of compounds were added to each 48-well plates. long-term effects. Therefore, natural compounds The plates were then placed in the Daniovision could be promising agents, because of their multi- system (Noldus, Wageningen, The Netherlands), functional health effects and limited toxicity. wherein they were blocked from daylight and il- In this study we characterised a natural com- luminated from below with white light (255 lx) pound exhibiting a suvorexant-like profile, based from 4 pm to 7 pm and from 5 am to 4 pm. The on zebrafish behavioural analysis, and deter- behaviour of zebrafish in each well was monitored mined whether phenotype-based screening using using the Daniovision system with a resolution of zebrafish could serve as a screening model for 1280 × 960 pixels at 25 frames per seconds. Eight natural compounds with the desired mechanisms larvae were assigned to examine the effect of each of action. concentration of the compound. Two independent experiments were performed for each compound. The recorded videos and images were subject- Materials and Methods ed to Ethovision XT11 (Noldus) to analyse the behaviour of zebrafish in each well. The mean Ethical Approval velocity, total distance moved, distance to centre The investigation conformed to the Ethical zone (2 mm radius circle) of the well, frequency Guidelines established by the Institutional Animal entering the centre zone, turn angle, and mobil- Care and Use Committee of Mie University, Japan. ity were measured. The parameters used in this behavioural analysis are shown in Figure 1-a. Compounds Mobility was calculated by taking every pixel Haloperidol, Chlorpromazine hydrochloride, identified as the subject and comparing it with the and Imipramine hydrochloride were purchased current image and the previous one. If all the pix- from Tokyo chemical industry (TCI) (Tokyo, Ja- els were the same, this would indicate zero mo- pan). Diazepam and Clonazepam were purchased bility. If all the pixels were different, this would from Sigma-Aldrich (St. Louis, MO, USA). Su- indicate 100% mobility. In this study, we defined vorexant was purchased from Toronto research 5%-35%, 35%-65%, and 65%-95% as low, medi- chemicals (North York, ON, Canada). These um, and high mobility, respectively14. compounds were dissolved in dimethyl sulfoxide Behavioural endpoints were measured: the (DMSO; Nacalai Tesque, Kyoto, Japan) to make distance moved total (DMT), distance to the zone stock solutions. in the centre of the well (DTZ), in zone frequen- cy (IZF), and turn angle (TA) in each mobility Zebrafish Husbandry category for each period (L1-time, the first light In this study, the nacre/rose/fli1: egfp zebrafish time period for 3 h; D-time, dark time period for was obtained by cross-breeding nacre (−/−)/rose 10 h; L2-time, second light time period for 11 h), (−/−) mutants and Tg (fli1: egfp) transgenic zebraf- resulting in 36 measured endpoints. Overview ish as described previously12. The zebrafish were of the behavioural analysis used in this study is incubated at 28°C under a 14 h light: 10 h dark cy- shown in Figure 1-b. The means obtained were cle and, in environmental quality water, according compared by analysis of variance using Prism 7 to The Zebrafish Book13. Embryos were obtained (GraphPad, La Jolla, CA, USA). Alpha was set at via natural mating and cultured in 0.3× Danieau’s 0.05 and Dunnett’s multiple comparisons test was solution [19.3 mM NaCl, 0.23 mM KCl, 0.13 mM used for post hoc analyses when significant dif- MgSO4, 0.2 mM Ca (NO3)2, 1.7 mM HEPES, pH ferences were observed. 7.2] until 8 days post-fertilization (dpf). For hierarchical clustering, the data for each behavioural endpoint were normalized according Behavioural Analysis to the controls. Hierarchical clustering was per- The behavioural assay was performed on 48 formed using MultiExperiment viewer. zebrafish at 8 dpf. Each zebrafish was placed into a well on a round 48-well plate (10 mm diameter, Natural Product Library for in-silico Assay 300 μl of 0.3× Danieau’s solution) at 12 pm. The To perform an in silico assay, a natural prod- 48-well plates were then placed in an incubator uct library was constructed, consisting of 9334 set at 28°C with constant light (255 lx) from 12 plants-derived compounds, including 8b. The pm to 3:30 pm. After incubation, 300 μl of 0.3× products were collected from AnalytiCon (Pots- Danieau’s solution with or without the sample dam, Germany), App Tec (Shanghai, China), 5128 A novel orexin antagonist from a natural plant was discovered using zebrafish behavioural analysis Figure 1. Larval zebrafish be- havioural assay was scored based on the following parameters: A, Illus- tration of the behavioural analysis parameters; B, Overview of the be- havioural analysis used in this study. A B BioBioPha (Yunnan, China), Biopurify (Sichuan, consist of suvorexant, almorexant, SB-649868, China), Chemfaces (Hubei, China), and Pharmeks TCS-OX2-2921, and MK-369722. Suvorexant, alm- (Moscow, Russia). orexant, and SB-649868 exhibit antagonist activi- ties towards both OX1 and OX2 receptors. Collection of Known Antagonists for OX1 and OX2 Receptors In silico Assay Using Pharmacophore- We collected known antagonists of OX1 and Search and Docking Simulation OX2 receptors (Supplementary Figure 1). OX1 Pharmacophores of OX1 antagonists were con- antagonists consist of suvorexant15, almorexant16, structed and pharmacophore searches were per- SB-64986817, SB-33486718, SB-408124 and SB- formed using the natural product library in the 67404219, and GSK-105986520. OX2 antagonists Ligandscout software23,24. After 3D conformations 5129 M. Yamanaka, H. Iwata, K. Masuda, M. Araki, Y. Okuno, M. Okamura, J. Koiwa, T. Tanaka of the antagonists were generated, clusters were proximately 1 h at 23°C. To evaluate the antagonist created and categorized into two classes: (a) suv- effect, solutions containing 50 μl of orexin A were orexant, almorexant, SB-649868, and SB-674042, added to the cultured cells in the 96-well plates to (b) SB-334867 and SB-408124.
Load more

Recommended publications
  • AP English Literature Required Reading
    Kerr High School AP English Literature Summer Reading 2019 Welcome to AP Literature! I’m fairly certain you are parched and thirsty for some juicy reading after a year of analyzing speeches and arguments, so let us jump right in. After months of deliberation and careful consideration, I have chosen several pieces from as far back as 429 BC Athens, to 1200 AD Scotland, venturing on to Africa 1800s, and finishing up in 20th century Chicago. Grab your literary passport and join me as we meet various tragic heroes and discover their tragic flaws and tragic mistakes. You will learn the difference between an Aristotelian tragic hero and a Shakespearean tragic hero, not to mention gain a whole bunch of insight into the human condition and learn some ancient Greek in the process. I made sure each piece is available in PDF online. If you choose to use the online documents, be certain you are able to annotate and have quick access to the annotated text for class discussions. The only AP 4 summer writing you will do is five reading record cards. Four of your reading record cards could include all of the required summer reading pieces. It is my expectation that you earnestly read, annotate, and ponder each of the required pieces and be ready to launch into discussion after your summer reading exam. Heavily annotated notes on the four attached tragic hero articles and your handwritten reading record cards will count as one major grade and are due Thursday, August 15, by 3:00 pm. Instructions for the reading record cards are attached.
    [Show full text]
  • Neuroendocrine and Sympathetic Responses to an Orexin Receptor Antagonist, SB-649868, and Alprazolam Following Insulin-Induced Hypoglycemia in Humans
    Psychopharmacology (2014) 231:3817–3828 DOI 10.1007/s00213-014-3520-7 ORIGINAL INVESTIGATION Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and Alprazolam following insulin-induced hypoglycemia in humans Ameera X. Patel & Sam R. Miller & Pradeep J. Nathan & Ponmani Kanakaraj & Antonella Napolitano & Philip Lawrence & Annelize Koch & Edward T. Bullmore Received: 8 October 2013 /Accepted: 24 February 2014 /Published online: 26 April 2014 # The Author(s) 2014. This article is published with open access at Springerlink.com Abstract it has previously been validated using the insulin tolerance test Rationale The orexin-hypocretin system is important for (ITT) model in humans. translating peripheral metabolic signals and central neuronal Results Of the primary endpoints, ITT induced defined in- inputs to a diverse range of behaviors, from feeding, motiva- creases in pulse rate, plasma cortisol, and adrenocorticotropic tion and arousal, to sleep and wakefulness. Orexin signaling is hormone in the placebo condition, but these responses were thus an exciting potential therapeutic target for disorders of not significantly impacted by alprazolam or SB-649868 pre- sleep, feeding, addiction, and stress. treatment. Of the secondary endpoints, ITT induced a defined Objectives/methods Here, we investigated the low dose phar- increase in plasma concentrations of adrenaline, noradrena- macology of orexin receptor antagonist, SB-649868, on neu- line, growth hormone (GH), and prolactin in the placebo roendocrine, sympathetic nervous system, and behavioral re- condition. Alprazolam pre-treatment significantly reduced sponses to insulin-induced hypoglycemic stress, in 24 healthy the GH response to ITT (p<0.003), the peak electromyogra- male subjects (aged 18–45 years; BMI 19.0–25.9 kg/m2), phy (p<0.0001) and galvanic skin response (GSR, p=0.04)to using a randomized, double-blind, placebo-controlled, acoustic startle, the resting GSR (p=0.01), and increased within-subject crossover design.
    [Show full text]
  • Orexin Receptor Antagonists As Therapeutic Agents for Insomnia
    REVIEW ARTICLE published: 25 December 2013 doi: 10.3389/fphar.2013.00163 Orexin receptor antagonists as therapeutic agents for insomnia Ana C. Equihua 1, Alberto K. De La Herrán-Arita 2 and Rene Drucker-Colin 1* 1 Neuropatología Molecular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City, México 2 Center for Sleep Sciences and Medicine, Stanford University, Palo Alto, CA, USA Edited by: Insomnia is a common clinical condition characterized by difficulty initiating or maintaining Christopher J. Winrow, Merck, USA sleep, or non-restorative sleep with impairment of daytime functioning. Currently, Reviewed by: treatment for insomnia involves a combination of cognitive behavioral therapy (CBTi) Matthew R. Ebben, Weill Medical and pharmacological therapy. Among pharmacological interventions, the most evidence College of Cornell University, USA Gabriella Gobbi, McGill University, exists for benzodiazepine (BZD) receptor agonist drugs (GABAA receptor), although Canada concerns persist regarding their safety and their limited efficacy. The use of these Matt Carter, University of hypnotic medications must be carefully monitored for adverse effects. Orexin (hypocretin) Washington, USA neuropeptides have been shown to regulate transitions between wakefulness and Michihiro Mieda, Kanazawa University, Japan sleep by promoting cholinergic/monoaminergic neural pathways. This has led to the *Correspondence: development of a new class of pharmacological agents that antagonize the physiological Rene Drucker-Colin, Departamento effects of orexin. The development of these agents may lead to novel therapies for de Neurociencias, Instituto de insomnia without the side effect profile of hypnotics (e.g., impaired cognition, disturbed Fisiología Celular, Universidad arousal, and motor balance difficulties). However, antagonizing a system that regulates Nacional Autónoma de México, Circuito exterior S/N, Apdo.
    [Show full text]
  • The Hypothalamus and the Regulation of Energy Homeostasis: Lifting the Lid on a Black Box
    Proceedings of the Nutrition Society (2000), 59, 385–396 385 CAB59385Signalling39612© NutritionInternationalPNSProceedings Society in body-weight 2000 homeostasisG. of the Nutrition Williams Society et (2000)0029-6651©al.385 Nutrition Society 2000 593 The hypothalamus and the regulation of energy homeostasis: lifting the lid on a black box Gareth Williams*, Joanne A. Harrold and David J. Cutler Diabetes and Endocrinology Research Group, Department of Medicine, The University of Liverpool, Liverpool L69 3GA, UK Professor Gareth Williams, fax +44 (0)151 706 5797, email [email protected] The hypothalamus is the focus of many peripheral signals and neural pathways that control energy homeostasis and body weight. Emphasis has moved away from anatomical concepts of ‘feeding’ and ‘satiety’ centres to the specific neurotransmitters that modulate feeding behaviour and energy expenditure. We have chosen three examples to illustrate the physiological roles of hypothalamic neurotransmitters and their potential as targets for the development of new drugs to treat obesity and other nutritional disorders. Neuropeptide Y (NPY) is expressed by neurones of the hypothalamic arcuate nucleus (ARC) that project to important appetite-regulating nuclei, including the paraventricular nucleus (PVN). NPY injected into the PVN is the most potent central appetite stimulant known, and also inhibits thermogenesis; repeated administration rapidly induces obesity. The ARC NPY neurones are stimulated by starvation, probably mediated by falls in circulating leptin and insulin (which both inhibit these neurones), and contribute to the increased hunger in this and other conditions of energy deficit. They therefore act homeostatically to correct negative energy balance. ARC NPY neurones also mediate hyperphagia and obesity in the ob/ob and db/db mice and fa/fa rat, in which leptin inhibition is lost through mutations affecting leptin or its receptor.
    [Show full text]
  • Activation of Orexin System Facilitates Anesthesia Emergence and Pain Control
    Activation of orexin system facilitates anesthesia emergence and pain control Wei Zhoua,1, Kevin Cheunga, Steven Kyua, Lynn Wangb, Zhonghui Guana, Philip A. Kuriena, Philip E. Bicklera, and Lily Y. Janb,c,1 aDepartment of Anesthesia and Perioperative Care, University of California, San Francisco, CA 94143; bDepartment of Physiology, University of California, San Francisco, CA 94158; and cHoward Hughes Medical Institute, University of California, San Francisco, CA 94158 Contributed by Lily Y. Jan, September 10, 2018 (sent for review May 22, 2018; reviewed by Joseph F. Cotten, Beverley A. Orser, Ken Solt, and Jun-Ming Zhang) Orexin (also known as hypocretin) neurons in the hypothalamus Orexin neurons may play a role in the process of general an- play an essential role in sleep–wake control, feeding, reward, and esthesia, especially during the recovery phase and the transition energy homeostasis. The likelihood of anesthesia and sleep shar- to wakefulness. With intracerebroventricular (ICV) injection or ing common pathways notwithstanding, it is important to under- direct microinjection of orexin into certain brain regions, pre- stand the processes underlying emergence from anesthesia. In this vious studies have shown that local infusion of orexin can shorten study, we investigated the role of the orexin system in anesthe- the emergence time from i.v. or inhalational anesthesia (19–23). sia emergence, by specifically activating orexin neurons utilizing In addition, the orexin system is involved in regulating upper the designer receptors exclusively activated by designer drugs airway patency, autonomic tone, and gastroenteric motility (24). (DREADD) chemogenetic approach. With injection of adeno- Orexin-deficient animals show attenuated hypercapnia-induced associated virus into the orexin-Cre transgenic mouse brain, we ventilator response and frequent sleep apnea (25).
    [Show full text]
  • OREXIN ANTAGONISTS BELSOMRA (Suvorexant), DAYVIGO (Lemborexant)
    OREXIN ANTAGONISTS BELSOMRA (suvorexant), DAYVIGO (lemborexant) RATIONALE FOR INCLUSION IN PA PROGRAM Background Belsomra (suvorexant) and Dayvigo (lemborexant) are orexin receptor antagonists used to treat difficulty in falling and staying asleep (insomnia). Orexins are chemicals that are involved in regulating the sleep-wake cycle and play a role in keeping people awake (1-2). Regulatory Status FDA-approved indication: Orexin receptor antagonists are indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance (1-2). Orexin Antagonists are contraindicated in patients with narcolepsy (1-2). Orexin Antagonists are central nervous system (CNS) depressants that can impair daytime wakefulness even when used as prescribed. Medications that treat insomnia can cause next-day drowsiness and impair driving and other activities that require alertness. Orexin Antagonists can impair driving skills and may increase the risk of falling asleep while driving. People can be impaired even when they feel fully awake. Patients should also be made aware of the potential for next-day driving impairment, because there is individual variation in sensitivity to the drug (1-2). The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or mental illness that should be evaluated (1-2). Warnings and precautions that should be discussed with the patient on Orexin Antagonist therapy include adverse reactions on abnormal thinking and behavioral changes (such as amnesia, anxiety, hallucinations and other neuropsychiatric symptoms), complex behaviors (such as sleep- driving, preparing and eating food, or making phone calls), dose-dependent increase in suicidal ideation, and sleep paralysis which is the inability to move or speak for up to several minutes during sleep-wake transitions (1-2).
    [Show full text]
  • Merck & Co., Inc
    As filed with the Securities and Exchange Commission on February 25, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 _________________________________ FORM 10-K (MARK ONE) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2020 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 1-6571 _________________________________ Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth New Jersey 07033 (908) 740-4000 New Jersey 22-1918501 (State or other jurisdiction of incorporation) (I.R.S Employer Identification No.) Securities Registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on which Registered Common Stock ($0.50 par value) MRK New York Stock Exchange 1.125% Notes due 2021 MRK/21 New York Stock Exchange 0.500% Notes due 2024 MRK 24 New York Stock Exchange 1.875% Notes due 2026 MRK/26 New York Stock Exchange 2.500% Notes due 2034 MRK/34 New York Stock Exchange 1.375% Notes due 2036 MRK 36A New York Stock Exchange Number of shares of Common Stock ($0.50 par value) outstanding as of January 31, 2021: 2,530,315,668. Aggregate market value of Common Stock ($0.50 par value) held by non-affiliates on June 30, 2020 based on closing price on June 30, 2020: $195,461,000,000. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Orexin Reverses Cholecystokinin-Induced Reduction in Feeding
    ORIGINAL ARTICLE Orexin reverses cholecystokinin-induced reduction in feeding A. Asakawa,1 A. Inui,1 T. Inui,2 G. Katsuura,3 M. A. Fujino4 and M. Kasuga1 1Division of Diabetes, Digestive and Kidney Diseases, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan 2Inui Clinic, Osaka, Japan 3Shionogi Research Laboratories, Shionogi & Co Ltd, Shiga, Japan 4First Department of Internal Medicine, Yamanashi Medical University, Yamanashi, Japan Aim: This study was designed to investigate the effect of orexin on anorexia induced by cholecystokinin (CCK), a peripheral satiety signal. Methods: We administered orexin A (0.01±1 nmol/mouse) and CCK-8 (3 nmol/mouse) to mice. Food intake was measured at different time-points: 20 min, 1, 2 and 4 h post-intracerebroventricular (i.c.v.) or intraperitoneal (i.p.) administrations. Results: Intracerebroventricular-administered orexin significantly increased food intake in a dose-dependent man- ner. The inhibitory effect of i.p.-administered CCK-8 on food intake was significantly negated by the simultaneous i.c.v. injection of orexin in a dose-dependent manner. Conclusions: Orexin reversed the CCK-induced loss of appetite. Our results indicate that orexin might be a promising target for pharmacological intervention in the treatment of anorexia and cachexia induced by various diseases. Keywords: orexin, cholecystokinin, mice, food intake, anorexia Received 28 March 2002; returned for revision 20 May 2002; revised version accepted 21 June 2002 Introduction However, the relationship between orexin and per- ipheral satiety systems still remains to be determined. Orexin is a hypothalamic neuropeptide identified as a We investigated the effect of orexin on anorexia induced ligand for an orphan G-protein coupled receptor [1±3].
    [Show full text]
  • ELEMENTS of FICTION – NARRATOR / NARRATIVE VOICE Fundamental Literary Terms That Indentify Components of Narratives “Fiction
    Dr. Hallett ELEMENTS OF FICTION – NARRATOR / NARRATIVE VOICE Fundamental Literary Terms that Indentify Components of Narratives “Fiction” is defined as any imaginative re-creation of life in prose narrative form. All fiction is a falsehood of sorts because it relates events that never actually happened to people (characters) who never existed, at least not in the manner portrayed in the stories. However, fiction writers aim at creating “legitimate untruths,” since they seek to demonstrate meaningful insights into the human condition. Therefore, fiction is “untrue” in the absolute sense, but true in the universal sense. Critical Thinking – analysis of any work of literature – requires a thorough investigation of the “who, where, when, what, why, etc.” of the work. Narrator / Narrative Voice Guiding Question: Who is telling the story? …What is the … Narrative Point of View is the perspective from which the events in the story are observed and recounted. To determine the point of view, identify who is telling the story, that is, the viewer through whose eyes the readers see the action (the narrator). Consider these aspects: A. Pronoun p-o-v: First (I, We)/Second (You)/Third Person narrator (He, She, It, They] B. Narrator’s degree of Omniscience [Full, Limited, Partial, None]* C. Narrator’s degree of Objectivity [Complete, None, Some (Editorial?), Ironic]* D. Narrator’s “Un/Reliability” * The Third Person (therefore, apparently Objective) Totally Omniscient (fly-on-the-wall) Narrator is the classic narrative point of view through which a disembodied narrative voice (not that of a participant in the events) knows everything (omniscient) recounts the events, introduces the characters, reports dialogue and thoughts, and all details.
    [Show full text]
  • Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use
    Role of the orexin receptor system in stress, sleep and cocaine use NCT02785406 Version Date: 04/25/2017 IRB NUMBER: HSC-MS-16-0120 IRB APPROVAL DATE: 04/25/2017 Title: Role of the orexin receptor system in stress, sleep and cocaine use Principal Investigator: Scott D. Lane Co-Investigators: Joy M. Schmitz, Charles E. Green, Jin H. Yoon, Michael F. Weaver ABSTRACT Preclinical research has established important functions for the orexin system in mediating arousal/sleep, stress, and cue-induced reinstatement of drug taking (e.g., relapse). The role of stress/anxiety and drug cue reactivity in human drug relapse is well established, but to date, the role of the orexin system in modulating these phenomena has not been examined in humans with substance use disorders (e.g., cocaine). The goal of the present first-in-human study will be to examine the effects of an orexin antagonist (suvorexant) on interactions among stress/anxiety, sleep, and drug-cue reactivity. We will utilize a battery of highly sensitive, drug-specific, laboratory measures of drug cue reactivity (a relapse risk model), and well-established metrics of stress/anxiety and sleep. We hypothesize that antagonism of the orexin system will attenuate the link between (1) stress/anxiety and drug cue reactivity, and (2) sleep and drug cue reactivity. These results will elucidate a unique biochemical mechanism for understanding relapse, and provide a potential medication target for relapse prevention SCIENTIFIC IMPACT Given the promising preclinical data on the orexin system in modulating sleep, anxiety, and drug cue reactivity, this research project has high translational scientific value.
    [Show full text]
  • Fiction Nonfiction Elements of Plot
    ENGLISH I – HONORS FALL 2016 FINAL EXAM REVIEW Format: The format of the Fall 2016 Final will be 45 multiple choice questions in EOC Test Format and two short answer prompts (one single selection and one crossover question). You will apply many of the skills on this list to new passages (e.g., a new short story or poem). **Please note that even though we covered To Kill a Mockingbird during the second six weeks, the test will NOT focus on your knowledge of the novel but your application of skills and concepts developed during the novel study.** 1ST SIX WEEKS: VOICE/ COUGAR WRITING CAMP 3RD SIX WEEKS: RHETORICAL & NONFICTION Syntax (Sentence Structure) Rhetoric Diction (Word Choice) Rhetorical Appeals Tone (Writer’s/Speaker’s Attitude) - Pathos Imagery (Sensory Language) - Ethos Inference (Interpreting Text) - Logos Diction (word choice) 1ST SIX WEEKS: DEFINING STYLE - Concrete Diction - Abstract Diction Fiction - Colloquialism Nonfiction - Formal Diction Elements of Plot Syntax (sentence structure) - Exposition - Anaphora/Epistrophe - Rising Action (Complications) - Asyndeton/Polysyndeton - Climax - Antithesis/Juxtaposition - Falling Action - Parallelism - Resolution - Rhetorical Questions Conflict (internal and external) Other Rhetorical Strategies Characters - Hyperbole - Protagonist - Apostrophe - Antagonist - Euphemism Analyzing Fiction: - Allusions (Historical, Literary, Mythological, Biblical) - Symbols CAPP (Context, Audience, Persona, Purpose) - Imagery (sight, sound, smell, touch, taste) Literary Nonfiction - Figurative language
    [Show full text]
  • Neuropeptides Controlling Energy Balance: Orexins and Neuromedins
    Neuropeptides Controlling Energy Balance: Orexins and Neuromedins Joshua P. Nixon, Catherine M. Kotz, Colleen M. Novak, Charles J. Billington, and Jennifer A. Teske Contents 1 Brain Orexins and Energy Balance ....................................................... 79 1.1 Orexin............................................................................... 79 2 Orexin and Feeding ....................................................................... 80 3 Orexin and Arousal ....................................................................... 83 J.P. Nixon • J.A. Teske Veterans Affairs Medical Center, Research Service (151), Minneapolis, MN, USA Department of Food Science and Nutrition, University of Minnesota, 1334 Eckles Avenue, St. Paul, MN 55108, USA Minnesota Obesity Center, University of Minnesota, 1334 Eckles Avenue, St. Paul, MN 55108, USA C.M. Kotz (*) Veterans Affairs Medical Center, GRECC (11 G), Minneapolis, MN, USA Veterans Affairs Medical Center, Research Service (151), Minneapolis, MN, USA Department of Food Science and Nutrition, University of Minnesota, 1334 Eckles Avenue, St. Paul, MN 55108, USA Minnesota Obesity Center, University of Minnesota, 1334 Eckles Avenue, St. Paul, MN 55108, USA e-mail: [email protected] C.M. Novak Department of Biological Sciences, Kent State University, Kent, OH, USA C.J. Billington Veterans Affairs Medical Center, Research Service (151), Minneapolis, MN, USA Veterans Affairs Medical Center, Endocrine Unit (111 G), Minneapolis, MN, USA Department of Food Science and Nutrition, University of Minnesota, 1334 Eckles Avenue, St. Paul, MN 55108, USA Minnesota Obesity Center, University of Minnesota, 1334 Eckles Avenue, St. Paul, MN 55108, USA H.-G. Joost (ed.), Appetite Control, Handbook of Experimental Pharmacology 209, 77 DOI 10.1007/978-3-642-24716-3_4, # Springer-Verlag Berlin Heidelberg 2012 78 J.P. Nixon et al. 4 Orexin Actions on Endocrine and Autonomic Systems ................................. 84 5 Orexin, Physical Activity, and Energy Expenditure ....................................
    [Show full text]